Valence8 US’s Tyra Biosciences TYRA Stock Holding History

Valence8 US’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,188	Closed	-$310K	–	57
2024 Q3	$310K	Buy	+13,188	New	+$277K	0.13%	33

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CPX

Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return

APMC

Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Valence8 US's TYRA Position: Q4 2024 in Review

Valence8 US sold out of Tyra Biosciences (TYRA) in Q4 2024, closing a stake of 13,188 shares — an estimated $310K sold.

Valence8 US first reported a position in TYRA in Q3 2024 and held it in 1 quarter. The position peaked at $310K in Q3 2024. 113 funds tracked by Wall St. Rank hold TYRA as of Q4 2024.

Valence8 US reported no remaining Tyra Biosciences position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 13,188 Tyra Biosciences shares in Q4 2024, an estimated $310K.
Valence8 US first reported a position in Tyra Biosciences in Q3 2024 and held it in 1 quarter.
Valence8 US's Tyra Biosciences position peaked at $310K in Q3 2024.
113 funds tracked by Wall St. Rank held Tyra Biosciences as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.